Skip to main content

Table 3 Effective rate according to the ACR20, ACR50, and ACR70

From: A multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Tong Luo Hua Shi capsule, a modernized Tibetan medicine, in patients with rheumatoid arthritis

  FAS, n (%) PPS, n (%)
ACR70 ACR50 ACR20 ACR70 ACR50 ACR20
TLHS 4.8 g 6 (10.2) 24 (40.7)**,**** 45 (76.3)*,*** 6 (11.3) 23 (43.4)**,**** 44 (83.0)**,****
TLHS 3.6 g 2 (3.4) 14 (23.7) 43 (72.9)* 2 (3.7) 14 (25.9) 42 (77.8)*,***
TLHS 2.4 g 1 (1.7) 9 (15.3) 33 (55.9) 1 (1.8) 9 (15.8) 33 (57.9)
Placebo 3 (5.1) 8 (13.6) 32 (54.2) 3 (5.8) 8 (15.4) 29 (55.8)
  1. ACR American College of Rheumatology response criteria, FAS full analysis set, PPS per protocol set
  2. *P < 0.05 versus the placebo group
  3. **P < 0.01 versus the placebo group
  4. ***P < 0.05 versus the 2.4 g group
  5. ****P < 0.01 versus the 2.4 g group
Back to article page

Trials

ISSN: 1745-6215